This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: YM Bio, Exact, Peregrine

As an investor, it's smart to be skeptical when presented with a press release purporting to describe the results of a clinical study, particularly a small phase II study. But as I said above, Peregrine gets credit for running a controlled study of bavi, which definitely lends credibility to the data announced Tuesday. It will be interesting to see how the data hold up as the study matures and additional results are reported.

Peregrine is an interesting challenge to the "Feuerstein-Ratain Rule", which states that an oncology drug company's market value is inversely correlated to the risk of phase III clinical failure. Granted, bavi is still in phase II studies, but Peregrine's market value of under $100 million suggests bavi has little chance of success. That the drug's been around a long time and has never generated interest from partners also weighs against it.

"The only thing that gives me pause is that the study was not blinded. Other than that, I see no holes," said Dr. Mark Ratain, a professor and oncologist at the University of Chicago and the co-inventor of the "Feuerstein-Ratain Rule."

Adds Ratain: "This is truly a test of our rule since the publicly disclosed data look pretty solid!"


Patrick A emails, "Please blast Spectrum Pharmaceuticals' (SPPI - Get Report) CEO, Raj Shrotriya. Please. I am a shareholder but I am absolutely sickened by the amount of compensation this guy receives. Yes, the stock has had a nice run, but assuming Shrotriya gets his 520,000-share award this month, the total amount of shares awarded to Shrotriya in 2011 will be 2.87 million shares. Yes, 2.87 million shares in either awards or options in a single calendar year! This in addition to a $1.9 million cash bonus!

Am I wrong in considering this absolutely ridiculous? I am pissed off as a shareholder. The dude pays himself like he's running a multibillion-dollar large pharma with thousands of employees bringing in billions of revenue. Spectrum is a $800 million market value company with 150 employees. His compensation is ridiculous."

Well said. Shrotriya's compensation is obscene. He had a good year, no doubt. I even nominated him for the Best Biotech CEO of 2011 award. But Patrick is right, Spectrum's board pays Shrotriya as if he's running a highly profitable, large-cap biotech company. He's not.


John Paul writes, "I really don't know who the worst biotech CEO should be, but I pronounce you the winner in the homer sic Simpson lookalike contest."

Doh!

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
EXAS $22.49 0.00%
INCY $94.36 0.00%
PPHM $1.38 0.00%
SPPI $6.00 0.00%
AAPL $123.25 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs